Navigation Links
FDA clears test developed in partnership with VCU researcher
Date:5/22/2012

RICHMOND, Va. (May 22, 2012) The Food and Drug Administration has approved a new test to help physicians diagnose a group of rare cell disorders. The test, or assay, was developed by an expert at Virginia Commonwealth University in the field of mast cells.

Lawrence Schwartz, M.D., Ph.D., chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas Professor of Medicine at VCU, has spent more than 30 years researching mast cells. These cells are vital to the inflammatory process within the body and may play protective roles in wound healing and fighting infections.

"When a mast cell is triggered, it releases several strong chemicals into the body, including histamine and tryptase. Histamine causes itching, swelling, wheezing and sneezing and other signs and symptoms of allergic reactions," said Schwartz.

Mastocytosis, a group of rare chronic disorders found in both children and adults, is caused by the presence of too many of these mast cells in the body. If there are too many mast cells, the increased burden of chemicals released from these cells can cause several symptoms that range in intensity from mild to severe.

Because mast cells play a role in allergic reactions, the symptoms of mastocytosis are often similar to an allergic reaction. However, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The FDA has cleared ImmunoCAP Tryptase, a new diagnostic assay, to measure the level of tryptase in the blood as an aid in the diagnosis of systematic mastocytosis. A persistently elevated baseline level of tryptase is an indication of possible mastocytosis.

"A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool," said Schwartz.

VCU first licensed the assay in 1993 to Pharmacia, now named Thermo Fisher Scientific Inc. The assay has one FDA-approved application helping to diagnose mastocytosis and several potential applications, including the diagnosis of systemic anaphylaxis, the prediction of increased risk for future episodes of severe anaphylaxis and use by medical examiners to evaluate cause of death.

"When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death," said Schwartz.


'/>"/>
Contact: Frances Dumenci
fdumenci@vcu.edu
804-828-7701
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
2. FDA clears biomarker test for ovarian cancer
3. Researchers find process that clears cholesterol and could reverse major cause of heart attack
4. Flightless mosquitoes developed to help control dengue fever
5. New tool developed to help guide pancreatic cyst treatment
6. Innovative Technology Developed at AGH Accurately Monitors Healthcare Professionals' Handwashing Practices, Study Shows
7. Innovative Motorized and Mobile Medical Procedure Table Developed By MTI, Inc.
8. New scanning technology developed in £7M research center
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Human clinical trial of NIH-developed dengue vaccine begins
11. New diabetes risk assessment developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... ... September 21, 2018 , ... Liz Dudek, Director of Health Care Affairs for ... Chapter meeting of the Florida Assisted Living Association (FALA) at 10:00 a.m. at Tessera ... will provide an overview of the success of the first five years of Florida’s ...
(Date:9/22/2018)... Calif. (PRWEB) , ... September 22, 2018 , ... ... and sizes. In fact, there are actually 29 different categories listed in section ... include charitable or religious organizations (often referred to as a 501(c)(3)), private foundations, ...
(Date:9/15/2018)... , ... September 14, 2018 , ... ... among other funding, full FY 2019 appropriations for Labor, Health and Human Services ... for the evidence-based Teen Pregnancy Prevention (TPP) Program, and $286.5 million for the ...
(Date:9/12/2018)... ... , ... De Novo Strategies for Getting Your Medical Device Approved:, What is ... – 3:00 p.m. ET, http://www.fdanews.com/denovostrategies , What’s the best route for ... What are the best practices to win approval? , These are some of the ...
(Date:9/12/2018)... , ... September 13, 2018 , ... Glori Blends will ... the industry leaders. , The expo will include vendors, presentations, panel discussions and a ... to educate attendees on their award winning products and assist customers with the best ...
Breaking Medicine News(10 mins):
(Date:9/24/2018)... ... , ... CloudMine, a HIPAA-compliant cloud-based health care platform solution ... award-winning Connected Health Cloud (CHC) platform. The latest version of the Connected Health ... as the introduction of new data visibility and governance features. This platform update ...
(Date:9/23/2018)... ... September 23, 2018 , ... ... California according to a study published in the prestigious International Journal of ... California: A Pilot Serological Study” was written by microbiologist Marianne Middelveen from ...
(Date:9/15/2018)... ... September 14, 2018 , ... EnviroLeather™ by LDI, a leader ... with SmithGroup, the Carto.graph collection is a graphic expression of mapping the San ... SmithGroup’s healthcare interior designer, Aileen Avila-Banaag to design the Carto.graph Collection. “I was ...
Breaking Medicine Technology: